摘要
背景与目的细胞角蛋白19片段(cytokeratin 19 fragment,CYFRA21-1)是血液中的一种可溶性蛋白质,它可能是一种潜在的循环肿瘤标志物。本研究旨在探讨CYFRA21-1在非小细胞肺癌(non-small cell lung cancer,NSCLC)诊断中的应用价值。方法采用酶联免疫吸附法分别检测107例NSCLC患者和51例肺部良性疾病患者外周血中CYFRA21-1含量,应用受试者工作曲线(receiver operaing characteristic curves,ROC)对检测结果进行临床评价。结果 NSCLC组织与肺良性疾病组外周血CYFRA21-1水平差别有统计学意义(χ2=47.343,P<0.001);以3.3μg/L为诊断临界点,CYFRA21-1诊断NSCLC的敏感性和特异性分别为74.77%和76.47%,ROC曲线下面积为0.8139;NSCLC各病理类型之间CYFRA21-1水平差别无有统计学意义(χ2=0.450,P=0.799);外周血CYFRA21-1在广泛期(IIIb、IV)病例中明显高于局限期(I、II、IIIb)病例(χ2=7.057,P=0.008)。结论 CYFRA21-1作为肺癌肿瘤标志物具有相对较高的敏感性和特异性;血浆中CYFRA21-1水平升高提示肺癌患者可能已经发展为广泛期。
Background and objective Cytokeratin-19 fragment（CYFRA21-1） is a soluble protein in serum,and may be a useful circulating tumor marker. The aim of this study is to investigate the diagnostic value of the peripheral blood CYFRA21-1 in non-small cell lung cancer（NSCLC） . Methods The levels of peripheral blood CYFRA21-1 were detected in 107 patients with NSCLC and 51 patients with benign pulmonary diseases by enzyme linked immunosorbent assay,and ROC curve was used to analyse the results. Results Singificant difference of peripheral blood CYFRA21-1 levels was detected between the NSCLC group and benign pulmonary disease group（χ2=47.343,P0.001） . At the threshold of 3.3 ng/mL,sensitivity and specificity of CYFRA21-1 as a serologic marker were 74.77% and 76.47%,respectively for any cancer. ROC curve showed that the under-curve area（AUC） of CYFRA21-1 was 0.813 9. There was no significant difference of CYFRA21-1 between subtypes of NSCLC（χ2=0.450,P=0.799） . The peripheral blood CYFRA21-1 level was elevated significantly in the patients with extensive disease（IIIb,IV） compared with patients with limited disase（I,II,IIIb） （χ2=7.057,P=0.008） . Conclusion As a tumor marker CYFRA21-1 has relative high sensitivity and specificity for the diagnosis of NSCLC. Elevated peripheral blood CYFRA 21-1 levels were usually indicated extensive disease of NSCLC.
出处
《中国肺癌杂志》
CAS
2010年第12期1118-1121,共4页
Chinese Journal of Lung Cancer
